



Ironwood Pharmaceuticals, Inc.
Investor Relations Department
301 Binney Street, 2nd floor
Cambridge, MA 02142
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: IRWD ¹

Last Trade:	14.84
Trade Time:	1:46 PM ET Feb 22, 2018
Change:	0.29 ↑ (1.993%)
Day Range	14.62 - 15.07
52-Week Range	12.89 - 19.94
Volume	516,573
Market Cap. (\$M)	0.000
Shares Out (M)	0.000

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

At Ironwood, we're focused on delivering differentiated medicines to patients. If we do this efficiently and effectively, we hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. These are not small goals, but we believe they represent the best way to maximize long-term value for both patients and shareholders.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 15, 2018
[Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update](#)

Feb 1, 2018
[Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call](#)

Jan 16, 2018
[Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® \(linaclotide\) Patent Litigation](#)

Jan 2, 2018
[Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference](#)

Dec 21, 2017
[Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 22, 2017
[Annual Report \(10-K\)](#)

Apr 18, 2017
[Definitive Proxy Statement](#)

Nov 2, 2017
[Quarterly Report \(10-Q\)](#)

Aug 3, 2017
[Quarterly Report \(10-Q\)](#)

May 8, 2017
[Quarterly Report \(10-Q\)](#)